Surge In Partnerships And Licensing In China Highlights Need For Greater Flexibility
This article was originally published in PharmAsia News
As cross-border deals rise rapidly and finding new partners becomes harder in China, multinational drug makers must be flexible in their deal strategies. Seasoned executives from AstraZeneca, Bayer, Merck and Chinese startup Ascletis offer insights on what to look for in a dynamic market.
You may also be interested in...
Merck announced March 15 that it plans to invest $90 million over the next seven years in a nonprofit biomedical research center in San Diego dubbed the California Institute for Biomedical Research, or Calibr.
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.
Rapid changes in China prompt many pharma companies to shuffle strategies and accelerate personal changes. BMS is getting a new country GM, Pfizer Biopharma China GM is departing and Takeda BU head is stepping down.